ObsEva SA (OBSV)
|Net Income (ttm)||-82.08M|
|Day's Range||2.53 - 2.66|
|52-Week Range||1.86 - 5.55|
|Price Target||12.00 (+352.8%)|
|Est. Earnings Date||Nov 4, 2021|
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for pret... [Read more...]
Financial PerformanceFinancial Statements
According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 352.83% from the latest price.
ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids. The data were presented at the American Society for Reproductive Medicine (ASRM) 202...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 S...
- Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster -
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & ...
– Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagoli x for the treatment of severe adenomyosis –
ObsEva Announce s Relationship with Syneos Health to Commercialize Linzagolix
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -
GENEVA, Switzerland September 7 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today an...
These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Inform...
- Linzagolix (Yselty ® ) for uterine fibroids: US New Drug Application filing planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 -
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Liv...
- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-
GENEVA, Switzerland August 3 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today annou...
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigationa...
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyos...
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -
- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation -
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28,...
Geneva, Switzerland and Boston, MA – May 31 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive ...
Geneva, Switzerland and Boston, MA – May 25 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive h...
Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. The post OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today ap...